JP2024506847A - がんを処置および改善するための方法 - Google Patents

がんを処置および改善するための方法 Download PDF

Info

Publication number
JP2024506847A
JP2024506847A JP2023546266A JP2023546266A JP2024506847A JP 2024506847 A JP2024506847 A JP 2024506847A JP 2023546266 A JP2023546266 A JP 2023546266A JP 2023546266 A JP2023546266 A JP 2023546266A JP 2024506847 A JP2024506847 A JP 2024506847A
Authority
JP
Japan
Prior art keywords
aml
optionally
drug
formulation
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506847A5 (https=
JPWO2022165398A5 (https=
Inventor
カトリオナ ジェイミーソン，
ロバートソン， レスリー クルーズ
マイケル バーカート，
ラリサ バライアン，
フィービー モンダラ，
ケイラ メイソン，
レイモンド エイチ． ディープ，
ジェイムズ ラクレア，
トーマス ウィゼナント，
ウォーレン シー． チャン，
デル ウェルフ， インゲ ファン
ペギー ウェントワース，
ウェンシュエ マ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2024506847A publication Critical patent/JP2024506847A/ja
Priority to JP2025015025A priority Critical patent/JP2025065209A/ja
Publication of JP2024506847A5 publication Critical patent/JP2024506847A5/ja
Publication of JPWO2022165398A5 publication Critical patent/JPWO2022165398A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023546266A 2021-02-01 2022-02-01 がんを処置および改善するための方法 Pending JP2024506847A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015025A JP2025065209A (ja) 2021-02-01 2025-01-31 がんを処置および改善するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144378P 2021-02-01 2021-02-01
US63/144,378 2021-02-01
PCT/US2022/014663 WO2022165398A1 (en) 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015025A Division JP2025065209A (ja) 2021-02-01 2025-01-31 がんを処置および改善するための方法

Publications (3)

Publication Number Publication Date
JP2024506847A true JP2024506847A (ja) 2024-02-15
JP2024506847A5 JP2024506847A5 (https=) 2025-02-10
JPWO2022165398A5 JPWO2022165398A5 (https=) 2025-02-10

Family

ID=82654982

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023546266A Pending JP2024506847A (ja) 2021-02-01 2022-02-01 がんを処置および改善するための方法
JP2025015025A Pending JP2025065209A (ja) 2021-02-01 2025-01-31 がんを処置および改善するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015025A Pending JP2025065209A (ja) 2021-02-01 2025-01-31 がんを処置および改善するための方法

Country Status (7)

Country Link
US (1) US20240148688A1 (https=)
EP (1) EP4284519A4 (https=)
JP (2) JP2024506847A (https=)
CN (1) CN116829142A (https=)
AU (1) AU2022214463A1 (https=)
CA (1) CA3206959A1 (https=)
WO (1) WO2022165398A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254465A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352783A (ja) * 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
WO2007110704A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
US20180296524A1 (en) * 2015-09-23 2018-10-18 The Regents Of The University Of California Methods for detection and eradication of myeloid leukemia stem cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
JP4758915B2 (ja) 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
ATE493444T1 (de) 2004-10-18 2011-01-15 Nitto Denko Corp Intrazelluläre peptidabgabe
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352783A (ja) * 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
WO2007110704A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
US20180296524A1 (en) * 2015-09-23 2018-10-18 The Regents Of The University Of California Methods for detection and eradication of myeloid leukemia stem cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACS CHEM. BIOL., vol. 15, JPN6025051161, 2020, pages 669 - 674, ISSN: 0005752174 *
BLOOD, vol. 126(23), JPN6025051157, 2015, pages 567, ISSN: 0005752170 *
BLOOD, vol. 136,Supplement1, JPN6025051154, 2020, pages 8, ISSN: 0005752167 *
CELL REPORTS PHYSICAL SCIENCE, vol. 2020,1,100277, JPN6025051160, pages 1 - 8, ISSN: 0005752173 *
CELL STEM CELL, vol. 19, JPN6025051156, 2016, pages 599 - 612, ISSN: 0005752169 *
J. MED. CHEM., vol. 56, JPN6025051155, 2013, pages 6573 - 6575, ISSN: 0005752168 *
J. MED. CHEM., vol. 56, JPN6025051159, 2013, pages 6576 - 6582, ISSN: 0005752172 *
ORG. LETT., vol. 14, no. 21, JPN6025051158, 2012, pages 5396 - 5399, ISSN: 0005752171 *

Also Published As

Publication number Publication date
EP4284519A1 (en) 2023-12-06
EP4284519A4 (en) 2024-12-25
AU2022214463A1 (en) 2023-09-14
CN116829142A (zh) 2023-09-29
CA3206959A1 (en) 2022-08-04
JP2025065209A (ja) 2025-04-17
US20240148688A1 (en) 2024-05-09
WO2022165398A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
de Oliveira Silva et al. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model
TWI329025B (en) Compositions for delivery of drug combinations
JP4926256B2 (ja) 併用薬剤を送達するための組成物
KR102301175B1 (ko) 항종양 알칼로이드를 이용한 병용요법
Ling et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
KR101085203B1 (ko) 의약 전달용 인지질 나노입자
CN117159470A (zh) 脂质体包封的亲和性药物
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
JP2006523713A (ja) 薬剤併用物送達用組成物
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
US20220313608A1 (en) Treatment of breast cancer
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
Gabizon et al. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy
JP2025065209A (ja) がんを処置および改善するための方法
Mattern-Schain et al. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics
US9012422B2 (en) Method of treating acute myelogenous leukemia
KR102569052B1 (ko) 암의 치료를 위한 약제학적 조합물
ES2809460T3 (es) Nuevo método de producción de lipoplejo para administración local y fármaco antitumoral que utiliza lipoplejo
BR112019013983A2 (pt) tratamento de câncer pancreático
US20250339539A1 (en) Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof
WO2024254465A2 (en) Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration
Chan Nanoscale Coordination Polymers for Chemotherapeutic and Biological Cancer Therapy
Kianinejad Formulation and Characterization of Temozolomide-Loaded Niosomal Nanovesicles for Glioblastoma Treatment with Comparative Stability Studies to Liposomes
Forciniti In vitro studies on CSC-targeted therapy in pancreatic adenocarcinoma with nanoparticle formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260311